Auriga Maintains a 'Buy' on Jazz Pharmaceuticals (JAZZ); Can Prialt Reach $150 Mln in Revenue by 2016?

Auriga maintains a 'Buy' on Jazz Pharmaceuticals (NASDAQ: JAZZ) price target of $57.00.

Auriga analyst said, "Prialt reminds us a lot about Xyrem during its early days. Some of the common characteristics are: 1) Low market penetration; 2) Pricing flexibility; 3) A highly trained, focused sales force. We think it is probable that Prialt may reach $150 annual sales during 2016. With the potential growth of Prialt and Xyrem, we are becoming more confident that JAZZ is likely to offset potential revenue loss from Fazaclo LD and meet its 2012 guidance. Longer term, there may be additional upsides from Prialt. Market penetration is low for Prialt. Prialt is the only FDA-approved non-opioid intrathecal analgesic."

For an analyst ratings summary and ratings history on Jazz Pharmaceuticals click here. For more ratings news on Jazz Pharmaceuticals click here.

Shares of Jazz Pharmaceuticals closed at $45.75 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Jazz Pharmaceuticals (JAZZ) PT Raised to $283 at Morgan Stanley
• New Street Research Upgrades Micron Technology (MU) to Buy
• Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'